Russell Investments Group Ltd. Sells 10,305 Shares of Myriad Genetics, Inc. (MYGN)

Russell Investments Group Ltd. decreased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 612,566 shares of the company’s stock after selling 10,305 shares during the period. Russell Investments Group Ltd. owned approximately 0.82% of Myriad Genetics worth $28,337,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MYGN. Robeco Institutional Asset Management B.V. increased its holdings in shares of Myriad Genetics by 100.0% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 456,440 shares of the company’s stock worth $19,029,000 after buying an additional 228,220 shares during the last quarter. Creative Planning acquired a new stake in shares of Myriad Genetics during the 3rd quarter worth approximately $266,000. First Trust Advisors LP increased its holdings in shares of Myriad Genetics by 562.0% during the 3rd quarter. First Trust Advisors LP now owns 87,093 shares of the company’s stock worth $4,006,000 after buying an additional 73,936 shares during the last quarter. MCF Advisors LLC acquired a new stake in shares of Myriad Genetics during the 3rd quarter worth approximately $277,000. Finally, Fisher Asset Management LLC increased its holdings in shares of Myriad Genetics by 8.6% during the 3rd quarter. Fisher Asset Management LLC now owns 128,271 shares of the company’s stock worth $5,900,000 after buying an additional 10,185 shares during the last quarter. Institutional investors own 96.32% of the company’s stock.

NASDAQ:MYGN opened at $38.42 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86. The company has a market cap of $2.87 billion, a P/E ratio of 30.49, a P/E/G ratio of 2.36 and a beta of 0.51. Myriad Genetics, Inc. has a fifty-two week low of $27.27 and a fifty-two week high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 21st. The company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.05. The firm had revenue of $200.90 million during the quarter, compared to analysts’ expectations of $195.93 million. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The firm’s quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the company posted $0.30 EPS. As a group, equities analysts forecast that Myriad Genetics, Inc. will post 1.41 EPS for the current year.

A number of analysts have recently issued reports on MYGN shares. Barclays raised their price target on shares of Myriad Genetics from $35.00 to $38.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 22nd. Zacks Investment Research downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Piper Jaffray Companies upgraded shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $38.00 to $53.00 in a report on Wednesday, October 10th. BidaskClub upgraded shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 29th. Finally, Bank of America raised their price target on shares of Myriad Genetics from $20.00 to $31.00 and gave the stock an “underperform” rating in a report on Monday, July 16th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $40.60.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: NASDAQ

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply